Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis

Statins, the intestinal cholesterol transporter inhibitor (ezetimibe), and PCSK9 inhibitors can reduce serum LDL-C levels, leading to a significant reduction in cardiovascular events. However, these events cannot be fully prevented even when maintaining very low LDL-C levels. Hypertriglyceridemia an...

Full description

Bibliographic Details

Published in:	Metabolites
Main Authors:	Shizuya Yamashita, Manfredi Rizzo, Ta-Chen Su, Daisaku Masuda
Format:	Article
Language:	English
Published:	MDPI AG 2023-05-01
Subjects:	PPARα SPPARMα pemafibrate triglycerides dyslipidemia
Online Access:	https://www.mdpi.com/2218-1989/13/5/626